DB

David Brookes

Anatara Lifesciences Ltd | Executive Chairman, Executive Director
Dr Brookes has experience in the health and biotechnology industries and held Board positions in a number of ASX listed biotechnology companies, including as Chairman of genomics solutions company, RHS Ltd, which was acquired by PerkinElmer Inc (NYSE: PKI) in June 2018. Dr. Brookes maintains roles as a clinician and as a biotechnology industry consultant.

Companies and Roles

Company
Title
Tenure
Since
ANR
ANR
Anatara Lifesciences Ltd
  • Executive Chairman
  • Executive Director
2yrs, 10mthJun 2022
IVG
IVG
Invert Graphite Limited
  • Non-Executive Director
  • Non-Executive Chairman
6yrsApr 2019
TD1
TD1
TALI Digital Limited
  • Non-Executive Director
4yrs, 9mthJun 2020
DLM
DLM
Dominion Minerals Limited
  • Non-Executive Director
  • Non-Executive Chairman
6yrsApr 2019

Holdings

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
IVG
IVG
Invert Graphite Limited
30/12/24N/A4,901,250500,000N/A
ANR
ANR
Anatara Lifesciences Ltd
23/12/241,240,0005,290,0024,707,143N/A
TD1
TD1
TALI Digital Limited
30/06/24457,14421,185,71618,000,000N/A
ILA
ILA
30/04/24N/A140,00040,000N/A
DLM
DLM
Dominion Minerals Limited
31/12/23N/A4,901,250500,000N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
ANR
ANR
Anatara Lifesciences Ltd
23/12/24
Buy
500,000$0.050$25,000Participation in share purchase plan
ANR
ANR
Anatara Lifesciences Ltd
09/07/24
Issued
1,500,000$0.040$60,000Placement
ANR
ANR
Anatara Lifesciences Ltd
09/07/24
Issued
2,500,000$0.040$100,000Issue of options
ILA
ILA
30/04/24
Expiry
400,000$0.053$21,200Options expired
ILA
ILA
26/03/24
Issued
40,000$0.060$2,400Rights issue